Skila KOL Experts Featured in Pharmaceutical Executive Europe
Morris Plains, NJ, November
13, 2007 - Skila, A Sela2 Company, conveys it's experience and recommendations
in managing key opinion leaders in a recent article entitled: "Going
Global: A Paradigm Shift in KOL Management." The article, which appears
in the October 2007 issue of Pharmaceutical Executive Europe, describes
new trends and depicts a holistic approach to Key Opinion Leader Management.
Realizing that today's fast-paced global business environment mandates
coordination and transparency when it comes to managing KOL relationships,
Skila's experts in Key Opinion Leader Management, Simon Mason, Jillian
Lin and Karen Keneflick-Massand, have truly revolutionized the way
in which life science companies handle KOL Management. According to
Skila's experts, "The evolution of a truly global strategic approach
to KOL relationships demands a certain paradigm shift from focusing
solely on building external relationships on an activity-centred basis
to understanding the consequence of not having a well defined, internal
process and capability in place to tie activities to strategic initiatives
across the entire global organization."
The authors discuss these new trends and common hurdles in the implementation
of KOL programs in a global organization that touches opinion leaders
in many different ways. The article also describes the 6 Tenets of
KOL Management and focuses on how important this methodology is when
compliance with different regulatory bodies on a worldwide basis is
critical to the brand's success.
Skila, a BelHealth investment company, is a global technology and services company specializing in fully managed "Solution" as-a-Service (SaaS) product launch lifecycle management and engagement / relationship management solutions for the healthcare industry. Skila’s solutions address the broad needs of global marketing, medical, market access, executive and alliance management teams that include a unique methodology, robust technology and key continuous services for effectively managing global product launches, key opinion leader relationships, market access / managed care, business performance, competitive intelligence, and key partnerships and alliances.
Having developed strong relationships with a broad number of global pharmaceutical companies, Skila’s solutions have been deployed in 61 countries, supporting numerous global brands and more than 10 million user interactions. Skila’s long-standing commitment and understanding of customers’ needs has resulted in the exponential growth and adoption of our methodology, technology and continuous services as the business platform of choice for our clients.
BelHealth is a private healthcare investment fund. For more info, visit www.belhealth.com.
